Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loratadine + pseudoephedrine is an oral combination drug consisting of loratadine, a long-lasting second-generation antihistamine (H1 histamine receptor antagonist), and pseudoephedrine, a sympathomimetic decongestant. This combination is used to relieve symptoms associated with allergic rhinitis and the common cold, including nasal congestion, sneezing, runny nose (rhinorrhea), itchy or watery eyes or nose (pruritus and lacrimation), and sinus pain. Loratadine works by selectively blocking peripheral histamine H1 receptors to reduce allergy symptoms without causing significant sedation. Pseudoephedrine acts as an agonist at adrenergic receptors in the nasal mucosa, leading to vasoconstriction that reduces swelling of nasal passages and improves breathing. The product is available over-the-counter in various extended-release tablet formulations[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on loratadine + pseudoephedrine.